The economic disease burden of measles in Japan and a benefit cost analysis of vaccination, a retrospective study

BMC Health Services Research

Volumn 11, Issue , 2011, Pages

  Takahashi, Kenzo ^a,b   Ohkusa, Yasushi ^c   Kim, Jong Young ^d  

^a INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d Chiba Nishi General Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CHILD; COST BENEFIT ANALYSIS; COST OF ILLNESS; ECONOMICS; FACTUAL DATABASE; FEMALE; HEALTH CARE POLICY; HEALTH SERVICES RESEARCH; HUMAN; INFANT; JAPAN; MALE; MEASLES; PRESCHOOL CHILD; RETROSPECTIVE STUDY; STATISTICAL MODEL; VACCINATION;

ADOLESCENT; ADULT; AGE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DATABASES, FACTUAL; FEMALE; HEALTH POLICY; HEALTH SERVICES RESEARCH; HUMANS; INFANT; JAPAN; MALE; MEASLES; MEASLES VACCINE; MODELS, ECONOMETRIC; RETROSPECTIVE STUDIES; VACCINATION; YOUNG ADULT;

EID: 80053533736     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-11-254     Document Type: Article

References (31)

1. Development of vaccination policy in Japan: current issues and policy directions. Nakatani H, Sano T, Iuchi T, Jpn J Infect Dis 2002 55 101 111 12403906 (Pubitemid 35378922)
2. The Current State of Immunization Administration in Japan. Enami T, Otsubo H, Japan Medical Association Journal 2010 53 2 111 117
3. Why is measles still endemic in Japan? Gomi H, Takahashi H, The Lancet 2004 364 9431 328 329 (Pubitemid 38970005)
4. Progress toward measles elimination - Japan, 1999-2008. Center for Disease Control and Prevention (CDC), MMWR Morb Mortal Wkly Rep 2008 57 1049 1052 18818586
5. A written request for implementation of effective control measures of measles epidemics. Submitted to the Ministry of Health, Labor and Welfare in July, 2001 (in Japanese). Japan Pediatric Society, Japanese Society of Child Health, Japan Pediatric Association, Infectious Agents Surveillance Report (IASR) 2001 http://idsc.nih.go.jp/iasr/22/261/dj2618.html (Acccessed on August 5, 2010)
6. Measles, Japan, 1999-2001. National Institute of Infectious Diseases, Japan, IASR Infectious Agents Surveillance Report 2001 22 273 274 http://idsc.nih.go.jp/iasr/22/261/tpc261.html (Acccessed on August 5, 2010)
7. The present status of measles in Japan as of 1998. National Institute of Infectious Diseases, Japan, IASR Infectious Agents Surveillance Report 1999 20 2 http://idsc.nih.go.jp/iasr/20/228/tpc228.html (Acccessed on August 5, 2010)
8. Measles, Japan, 2001-2003. National Institute of Infectious Diseases, Japan, IASR Infectious Agents Surveillance Report 2004 25 60 61 http://idsc.nih.go.jp/iasr/25/289/tpc289.html (Acccessed on August 5, 2010)
9. [Cumulative vaccination coverage of measles- and oral polio vaccine obtained by the nationwide survey (in Japanese)]. Takayama N, Sakiyama H, Miyamura T, Kato T, Kansenshogaku Zasshi 2005 79 1 7 12 15717477
10. Measles vaccine coverage and factors related to uncompleted vaccination among 18-month-old and 36-month-old children in Kyoto, Japan. Matsumura T, Nakayama T, Okamoto S, Ito H, BMC Public Health 2005 5 (59)
11. Japan's medical care system. Iglehart JK, N Engl J Med 1988 319 12 807 812 10.1056/NEJM198809223191234 3412412
12. Policy evaluation for the subsidy for influenza vaccination in elderly. Ohkusa Y, Vaccine 2005 23 (17 18):2256-2260
13. [Cost-effectiveness analysis of routine immunization for varicella in Japan (in Japanese)]. Sugawara T, Ohkusa Y, Oikawa K, Haneda N, Kikuchi K, Kato F, Yamaguchi S, Okabe N, Kansenshogaku Zasshi 2006 80 3 212 219 16780127
14. Economic evaluation of vaccination programs: the impact of herd-immunity. Brisson M, Edmunds WJ, Med Decis Making 2003 23 76 82 10.1177/0272989X02239651 12583457 (Pubitemid 36133362)
15. Measles. Cherry J, Feigin&CHERRYs TEXTBOOOK of pediatric infectious diseases Volume 6th edition New York: Elsevir, Cherry J, Kaplan S, Demmler-Harrison G, Steinbach W, 2009 2427 2450 21898114
16. Specified Report of Vital Statistics in FY2007(in Japanese). http://www.mhlw.go.jp/english/database/db-hw/vs04.html (Acccessed on August 5, 2010)
17. Mesles. Committee on Infectious Diseases, 2003 Red Book Report of the Committee on Infectious Diseases Elk Grove Village, IL: American Academy of Pediatrics, Pickering LK, Baker CF, Kimberlin DW, Long SS, 28 2003 419 429
18. Action Plans to Control Measles and the Future Problems (in Japanese). National Institute of Infectious Diseases, Japan, Tokyo: National Institute of Infectious Diseases 2002 2 http://idsc.nih.go.jp/disease/measles/report2002/ measles-top.html (Acccessed on August 5, 2010)
19. Cost-benefit calculations of vaccinations against measles and mumps in Austria. Wiedermann G, Ambrosch F, Dev Biol Stand 1979 43 273 277 118067 (Pubitemid 10250914)
20. Costs and benefits of measles vaccination in Finland. Ekblom M, Elo O, Laurinkari J, Niemelä P, Scand J Soc Med 1978 6 3 111 115 103198 (Pubitemid 9067537)
21. Economic evaluation of options for measles vaccination strategy in a hypothetical Western European country. Beutels P, Gay NJ, Epidemiol Infect 2003 130 2 273 283 10.1017/S0950268802008142 12729196 (Pubitemid 36511967)
22. A benefit-cost analysis of two-dose measles immunization in Canada. Pelletier L, Chung P, Duclos P, Manga P, Scott J, Vaccine 1998 16 (9 10):989-996 10.1016/S0264-410X(97)00147-3 9607003 (Pubitemid 27504798)
23. An economic analysis of the current universal 2-dose measles-mumps- rubella vaccination program in the United States. Zhou F, Reef S, Massoudi M, Papania MJ, Yusuf HR, Bardenheier B, Zimmerman L, McCauley MM, J Infect Dis 2004 189 Suppl 1 131 145 15106102
24. Strategic planning for measles control: using data to inform optimal vaccination strategies. Simons E, Mort M, Dabbagh A, Strebel P, Wolfson L, J Infect Dis 2011 204 Suppl 1 28 34 21666174
25. The cost-effectiveness of supplementary immunization activities for measles: a stochastic model for Uganda. Bishai D, Johns B, Nair D, Nabyonga-Orem J, Fiona-Makmot B, Simons E, Dabbagh A, J Infect Dis 2011 204 Suppl 1 107 115 21666151
26. Hepatitis B virus eradication strategy for Asia. The Asian Regional Study Group. Sung JL, Vaccine 1990 8 3 95 99 2139290
27. Economic impact of influenza vaccination in preschool children. Cohen G, Nettleman M, Pediatrics 2000 106 5 973 976 10.1542/peds.106.5.973 11061762
28. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Nichol KL, Arch Intern Med 2001 161 5 749 759 10.1001/archinte.161.5.749 11231710 (Pubitemid 32200231)
29. The effectiveness of vaccination against influenza in healthy working adults. Nichol KL, Lind A, Margolis K, Murdoch M, McFadden R, Hauge M, Magnan S, Drake M, N Eng J Med 1995 333 889 893 10.1056/NEJM199510053331401
30. Private Vaccination and Public Health: An Empirical Examination for U.S. Measles. Philipson T, J Hum Resour 1996 31 3 611 630 10.2307/146268 (Pubitemid 126598414)
31. Marthe RG, Siegel JE, Russel LB, Weinstein MC, Cost-Effectiveness in Health and Medicine Oxford University Press 1966